Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
| Class:Id | LiteratureReference:9702216 |
|---|
| _displayName | Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial |
|---|
| _timestamp | 2020-09-29 20:55:19 |
|---|
| author | [Person:9700355] Shaw, Alice T
[Person:9702221] Gandhi, Leena
[Person:9702225] Gadgeel, Shirish
[Person:9646839] Riely, Gregory J
[Person:9702230] Cetnar, Jeremy
[Person:9702229] West, Howard
[Person:9701748] Camidge, D Ross
[Person:9702218] Socinski, Mark A
[Person:9702227] Chiappori, Alberto
[Person:9702231] Mekhail, Tarek
[Person:9702217] Chao, Bo H
[Person:9702223] Borghaei, Hossein
[Person:9702219] Gold, Kathryn A
[Person:9702226] Zeaiter, Ali
[Person:9702224] Bordogna, Walter
[Person:9702215] Balas, Bogdana
[Person:111116] Puig, O
[Person:9702222] Henschel, Volkmar
[Person:9634500] Ou, Sai-Hong Ignatius |
|---|
| created | [InstanceEdit:9702220] Rothfels, Karen, 2020-09-29 |
|---|
| journal | Lancet Oncol. |
|---|
| modified | [InstanceEdit:9729686] Rothfels, Karen, 2021-05-03 |
|---|
| pages | 234-242 |
|---|
| pubMedIdentifier | 26708155 |
|---|
| title | Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial |
|---|
| volume | 17 |
|---|
| year | 2016 |
|---|
| (literatureReference) | [Reaction:9700662] Liganded-ALK dimer binds type I ALK-binding TKIs [Homo sapiens] |
|---|
|
[Change default viewing format]
|
No pathways have been reviewed or authored by Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial (9702216)
